Provided by Tiger Trade Technology Pte. Ltd.

Entera Bio Ltd.

2.96
+0.10003.50%
Pre-market: 2.76-0.2000-6.76%05:20 EDT
Volume:777.61K
Turnover:2.32M
Market Cap:512.08M
PE:-8.37
High:3.05
Open:2.86
Low:2.79
Close:2.86
52wk High:4.20
52wk Low:0.9100
Shares:173.00M
Float Shares:138.87M
Volume Ratio:2.24
T/O Rate:0.56%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.3536
EPS(LYR):-0.2476
ROE:-138.92%
ROA:-45.98%
PB:70.48
PE(LYR):-11.95

Loading ...

Press Release: Entera Announces First Quarter 2026 Financial Results and Updates Across its Oral Peptide Programs

Dow Jones
·
May 09

Entera Bio Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Apr 27

Entera Bio prices $10 million private placement led by BVF Partners

Reuters
·
Apr 07

Entera Bio prices USD 10 million private placement led by BVF Partners

Reuters
·
Apr 02

Stock Market Today: S&P 500, Dow Futures Gain As Trump Calls Iran's New Leaders 'Very Reasonable'—Palantir, Rezolve AI, Entera Bio In Focus

Benzinga_recent_news
·
Mar 30

Phreesia, Progress Software And 3 Stocks To Watch Heading Into Monday

Benzinga Earnings
·
Mar 30

Entera Bio Q4 EPS $(0.06) Beats $(0.09) Estimate

Benzinga Earnings
·
Mar 28

Entera Bio FY2025 operating expenses rise 19.79% to $12 million; net loss widens to $11 million on no revenue

Reuters
·
Mar 28

Press Release: Entera Bio Announces Full Year 2025 Financial Results and Provides Business Updates

Dow Jones
·
Mar 28

Entera Bio Ltd expected to post a loss of 9 cents a share - Earnings Preview

Reuters
·
Mar 25

Entera Bio Director Geno J Germano Acquires Entera Bio Common Shares

Reuters
·
Mar 11

Entera Bio Moves Toward Phase 3 With Oral Therapy That Could Transform Osteoporosis Treatment (NASDAQ: ENTX)

TIPRANKS
·
Mar 05

Entera Bio Submits Streamlined Phase 3 Protocol To Initiate Registrational Program For Eb613 In Postmenopausal Women With Osteoporosis

Reuters
·
Mar 04

Entera Bio Submits Streamlined EB613 Phase 3 Protocol Amendment to FDA

Reuters
·
Mar 04

Entera Bio Submits Streamlined Phase 3 Protocol to Initiate Registrational Program for EB613 in Postmenopausal Women with Osteoporosis

GlobeNewswire
·
Mar 04